Below is a post I put on the other board showing m
Post# of 72440
A mighty river starts with many small tributaries feeding it. In time, the combining of all these small streams results in a major flowing river.
Today's PR and your articles show IMO that Brilacidin is quickly flowing and turning into a mighty river. From now on I will think of it as the Amazon of new drugs coming on the market.
It doesn't take much imagination to identify the steadily forward and increasingly important steps being taken by mgt to make the OM/IBD indications worth a great deal of money and for which offers are currently being negotiated.
The only real imagination comes from those trying to pass the steady stream of great news off as something other than pure gold.
The 2 largest steps needed to be overcome to make IPIX a gold mine are getting both Brilacidin and Kevetrin into acceptable pill formulations. We knew that Kevetrin was pretty well advanced towards meeting the goal, today we find out that Brilacidin also took a big step forward by performing extremely well in initial gastric testing and appears to be well on it's way to becoming the IBD workhorse we have been expecting. I don't see any fluff in the following statement from the PR:
"This finding should enable initial clinical testing with a simple formulation of the drug candidate delivered to the gut while a more elegant, tailored oral dosage form of Brilacidin is developed and refined, in parallel. The end goal would be to release Brilacidin selectively in the GI tract via targeted delivery technology."
Major step forward for IPIX, thank you management!!